日本 欧美 国内 一区二区-亚洲一区在线播放网站-99久久久精品免费看国产-中文字幕丰满乱孑伦无码专区-亚洲国产精品无码专区在线观看-国产成人片无码视频在线观看-一区二区欧美日韩高清免费-国产成人无精品久久久久国语-欧美精品在线观看一区二区

Citations文獻(xiàn)/文章

您可通過下方引文搜索引擎搜索Promega為您推薦的產(chǎn)品應(yīng)用文章。從“應(yīng)用方向”中選擇一個(gè)或多個(gè)應(yīng)用方向,并/或在文本框中直接輸入搜索關(guān)鍵詞。 引文來自使用Promega產(chǎn)品的出版物。搜索結(jié)果將包括期刊名稱、文章標(biāo)題、發(fā)表作者、關(guān)鍵

引文搜索指導(dǎo)

查看引文搜索小技巧

我們的引文數(shù)據(jù)庫包含引用Promega產(chǎn)品的同行評審期刊文章。有以下多種方法可以搜索引文:

  • 在文本字段中直接輸入關(guān)鍵詞(包括目錄號(hào)、產(chǎn)品名稱或作者)。
  • 在“選擇應(yīng)用方向”列表中選擇一個(gè)或多個(gè)“應(yīng)用方向”。
  • 選擇應(yīng)用方向并輸入關(guān)鍵詞。直接按照文章發(fā)表年份搜索。

對于使用特定Promega產(chǎn)品的引文,我們建議您按產(chǎn)品名稱或目錄號(hào)進(jìn)行搜索。對于范圍更廣的搜索,建議您選擇一個(gè)或兩個(gè)應(yīng)用方向查看結(jié)果,然后通過向搜索條件添加關(guān)鍵詞來縮小焦點(diǎn)。
符合搜索條件的引文將按時(shí)間倒序顯示(較新的引用文章優(yōu)先顯示)。關(guān)于特定產(chǎn)品的更多信息,請參閱 引文及技術(shù)文章分析或 操作說明。

篩選項(xiàng)清空

研究/應(yīng)用方向

產(chǎn)品/技術(shù)

選擇引文起止時(shí)間

  • Next-generation sequencing coupled with a cell-free display technology for high-throughput production of reliable interactome data

    Scientific Reports | 2021 | 查看原文 |

    作者:Shigeo Fujimori, Naoya Hirai, Hiroyuki Ohashi, Kazuyo Masuoka, Akihiko Nishikimi, Yoshinori Fukui, Takanori Washio, Tomohiro Oshikubo, Tatsuhiro Yamashita & Etsuko Miyamoto-Sato

    摘要:Next-generation sequencing (NGS) has been applied to various kinds of omics studies, resulting in many biological and medical discoveries. However, high-throughput protein-protein interactome datasets derived from detection by sequencing are scarce, because protein-protein interaction analysis requires many cell manipulations to examine the interactions. The low reliability of the high-throughput data is also a problem. Here, we describe a cell-free display technology combined with NGS that can improve both the coverage and reliability of interactome datasets. The completely cell-free method gives a high-throughput and a large detection space, testing the interactions without using clones. The quantitative information provided by NGS reduces the number of false positives. The method is suitable for thein vitrodetection of proteins that interact not only with the bait protein, but also with DNA, RNA and chemical compounds. Thus, it could become a universal approach for exploring the large space of protein sequences and interactome networks.
    展開

    關(guān)鍵詞:RiboMAX體外轉(zhuǎn)錄,cDNA文庫,基因表達(dá),蛋白互作

    應(yīng)用產(chǎn)品:RiboMAX? Large-Scale RNA Production SystemsRibo m7G Cap Analog

  • CRISPR/Cas9-mediated precise genome modification by a long ssDNA template in zebrafish

    BMC Genomics | 2020 | 查看原文 |

    作者:Haipeng Bai, Lijun Liu, Ke An, Xiaochan Lu, Michael Harrison, Yanqiu Zhao, Ruibin Yan, Zhijie Lu, Song Li, Shuo Lin, Fang Liang & Wei Qin

    摘要:BackgroundGene targeting by homology-directed repair (HDR) can precisely edit the genome and is a versatile tool for biomedical research. However, the efficiency of HDR-based modification is still low in many model organisms including zebrafish. Recently, long single-stranded DNA (lssDNA) molecules have been developed as efficient alternative donor templates to mediate HDR for the generation of conditional mouse alleles. Here we report a method, zLOST (zebrafish long single-stranded DNA template), which utilises HDR with a long single-stranded DNA template to produce more efficient and precise mutations in zebrafish.ResultsThe efficiency of knock-ins was assessed by phenotypic rescue at thetyrosinase(tyr) locus and confirmed by sequencing. zLOST was found to be a successful optimised rescue strategy: using zLOST containing atyrrepair site, we restored pigmentation in at least one melanocyte in close to 98% of albinotyr25del/25delembryos, although more than half of the larvae had only a small number of pigmented cells. Sequence analysis showed that there was precise HDR dependent repair of thetyrlocus in these rescued pigmented embryos. Furthermore, quantification of zLOST knock-in efficiency at therps14,nop56andthloci by next generation sequencing demonstrated that zLOST showed a clear improvement. We utilised the HDR efficiency of zLOST to precisely model specific human disease mutations in zebrafish with ease. Finally, we determined that this method can achieve a germline transmission rate of up to 31.8%.ConclusionsIn summary, these results show that zLOST is a useful method of zebrafish genome editing, particularly for generating desired mutations by targeted DNA knock-in through HDR.
    展開

    關(guān)鍵詞:RiboMAX體外轉(zhuǎn)錄,基因編輯,CRISPR,疾病模型

    應(yīng)用產(chǎn)品:RiboMAX? Large-Scale RNA Production SystemsRibo m7G Cap Analog

  • Validation of a mitochondrial RNA therapeutic strategy using fibroblasts from a Leigh syndrome patient with a mutation in the mitochondrial ND3 gene

    Scientific Reports | 2020 | 查看原文 |

    作者:Yuma Yamada, Kana Somiya, Akihiko Miyauchi, Hitoshi Osaka & Hideyoshi Harashima

    摘要:We report on the validation of a mitochondrial gene therapeutic strategy using fibroblasts from a Leigh syndrome patient by the mitochondrial delivery of therapeutic mRNA. The treatment involves delivering normal ND3 protein-encoding mRNA as a therapeutic RNA to mitochondria of the fibroblasts from a patient with a T10158C mutation in the mtDNA coding the ND3 protein, a component of the mitochondrial respiratory chain complex I. The treatment involved the use of a liposome-based carrier (a MITO-Porter) for delivering therapeutic RNA to mitochondriaviamembrane fusion. The results confirmed that the mitochondrial transfection of therapeutic RNA by the MITO-Porter system resulted in a decrease in the levels of mutant RNA in mitochondria of diseased cells based on reverse transcription quantitative PCR. An evaluation of mitochondrial respiratory activity by respirometry also showed that transfection using the MITO-Porter resulted in an increase in maximal mitochondrial respiratory activity in the diseased cells.
    展開

    關(guān)鍵詞:RiboMAX體外轉(zhuǎn)錄,線粒體DNA突變,神經(jīng)退行性疾病

    應(yīng)用產(chǎn)品:RiboMAX? Large-Scale RNA Production SystemsRibo m7G Cap Analog

  • PbTTG1 forms a ribonucleoprotein complex with polypyrimidine tract-binding protein PbPTB3 to facilitate the long-distance trafficking of PbWoxT1 mRNA

    Science Direct | 2019 | 查看原文 |

    作者:Shengnan,WangShengyuan,WangWenna,ZhangQiulei,ZhangL,iHaoYi,ZhangChaoran,XuYunfei,YuBaoan,WangTianzhong,LiFengJiang

    摘要:The grafting of horticultural crops enables breeders to induce phenotypic changes in rootstocks and scions. A number of signaling molecules, including RNAs and proteins, were recently shown to underlie these changes; however, little is known about the composition of ribonucleoprotein (RNP) complexes or how these macromolecules are transported. Here, we used a polypyrimidine tract-binding protein, PbPTB3, as a bait to screen a library of phloem cDNA from a pear variety ‘Du Li’ (Pyrus betulaefolia). We identified a new protein constituent of the RNP complex, TRANSPARENT TESTA GLABRA1 (PbTTG1), a WD40 protein that interacts with PbPTB3 to facilitate its transport withPbWoxT1mRNA through the phloem. Overexpression experiments indicated that PbTTG1 binds to PbPTB3, facilitating its transmission from the leaf through the petiole, while silencing ofPbTTG1expression prevented their translocation. Heterografting experiments also showed that silencing ofPbTTG1prevented the transport of PbPTB3 from the rootstock to the scion. Collectively, these findings established that PbTTG1 binds to PbPTB3 andPbWoxT1to form an RNP complex, which facilitates their long-distance movement.
    展開

    關(guān)鍵詞:RiboMAX體外轉(zhuǎn)錄,嫁接,mRNA轉(zhuǎn)移

    應(yīng)用產(chǎn)品:RiboMAX? Large-Scale RNA Production SystemsRibo m7G Cap Analog

  • Cis- and trans-regulations of pre-mRNA splicing by RNA editing enzymes influence cancer development

    Nature Communications | 2020 | 查看原文 |

    作者:Sze Jing Tang, Haoqing Shen, Omer An, HuiQi Hong, Jia Li, Yangyang Song, Jian Han, Daryl Jin Tai Tay, Vanessa Hui En Ng, Fernando Bellido Molias, Ka Wai Leong, Priyankaa Pitcheshwar, Henry Yang &

    摘要:RNA editing and splicing are the two major processes that dynamically regulate human transcriptome diversity. Despite growing evidence of crosstalk between RNA editing enzymes (mainly ADAR1) and splicing machineries, detailed mechanistic explanations and their biological importance in diseases, such as cancer are still lacking. Herein, we identify approximately a hundred high-confidence splicing events altered by ADAR1 and/or ADAR2, and ADAR1 or ADAR2 protein can regulate cassette exons in both directions. We unravel a binding tendency of ADARs to dsRNAs that involves GA-rich sequences for editing and splicing regulation. ADAR1 edits an intronic splicing silencer, leading to recruitment of SRSF7 and repression of exon inclusion. We also present a mechanism through which ADAR2 binds to dsRNA formed between GA-rich sequences and polypyrimidine (Py)-tract and precludes access of U2AF65 to 3′ splice site. Furthermore, we find these ADARs-regulated splicing changes per se influence tumorigenesis, not merely byproducts of ADARs editing and binding.
    展開

    關(guān)鍵詞:RiboMAX體外轉(zhuǎn)錄,RNA編輯,剪切,相互作用

    應(yīng)用產(chǎn)品:RiboMAX? Large-Scale RNA Production SystemsRibo m7G Cap Analog

  • 結(jié)構(gòu)表位模擬物的開發(fā):HCV疫苗設(shè)計(jì)的獨(dú)特型方法

    npj Vaccines | 2021 | 查看原文 |

    作者:Vanessa M. Cowton, Ania M. Owsianka, Valeria Fadda, Ana Maria Ortega-Prieto, Sarah J. Cole, Jane A. Potter, Jessica K. Skelton, Nathan Jeffrey, Caterina Di Lorenzo, Marcus Dorner, Garry L. Taylor & Arv

    摘要:HCV vaccine development is stymied by the high genetic diversity of the virus and the variability of the envelope glycoproteins. One strategy to overcome this is to identify conserved, functionally important regions—such as the epitopes of broadly neutralizing antibodies (bNAbs)—and use these as a basis for structure-based vaccine design. Here, we report an anti-idiotype approach that has generated an antibody that mimics a highly conserved neutralizing epitope on HCV E2. Crucially, a mutagenesis screen was used to identify the antibody, designated B2.1?A, whose binding characteristics to the bNAb AP33 closely resemble those of the original antigen. Protein crystallography confirmed that B2.1?A is a structural mimic of the AP33 epitope. When used as an immunogen B2.1?A induced antibodies that recognized the same epitope and E2 residues as AP33 and most importantly protected against HCV challenge in a mouse model.
    展開

    關(guān)鍵詞:RiboMAX體外轉(zhuǎn)錄,HCV疫苗,中和抗體

    應(yīng)用產(chǎn)品:T7 RiboMAX? Express Large-Scale RNA Production System

  • 殘翅病毒的重疊感染排斥取決于序列一致性,而不是獲得病毒的順序

    The ISME Journal | 2021 | 查看原文 |

    作者:Olesya N. Gusachenko, Luke Woodford, Katharin Balbirnie-Cumming & David J. Evans

    摘要:Deformed wing virus (DWV) is the most important globally distributed pathogen of honey bees and, when vectored by the ectoparasiteVarroa destructor, is associated with high levels of colony losses. Divergent DWV types may differ in their pathogenicity and are reported to exhibit superinfection exclusion upon sequential infections, an inevitability in aVarroa-infested colony. We used a reverse genetic approach to investigate competition and interactions between genetically distinct or related virus strains, analysing viral load over time, tissue distribution with reporter gene-expressing viruses and recombination between virus variants. Transient competition occurred irrespective of the order of virus acquisition, indicating no directionality or dominance. Over longer periods, the ability to compete with a pre-existing infection correlated with the genetic divergence of the inoculae. Genetic recombination was observed throughout the DWV genome with recombinants accounting for ~2% of the population as determined by deep sequencing. We propose that superinfection exclusion, if it occurs at all, is a consequence of a cross-reactive RNAi response to the viruses involved, explaining the lack of dominance of one virus type over another. A better understanding of the consequences of dual- and superinfection will inform development of cross-protective honey bee vaccines and landscape-scale DWV transmission and evolution.
    展開

    關(guān)鍵詞:RiboMAX體外轉(zhuǎn)錄,病毒研究,疫苗研發(fā)

    應(yīng)用產(chǎn)品:RiboMAX? Large-Scale RNA Production SystemsRibo m7G Cap Analog

  • 流感病毒RNA合成過程中核糖核蛋白復(fù)合物的超微結(jié)構(gòu)

    Communications Biology | 2021 | 查看原文 |

    作者:Masahiro Nakano, Yukihiko Sugita, Noriyuki Kodera, Sho Miyamoto, Yukiko Muramoto, Matthias Wolf & Takeshi Noda

    摘要:The single-stranded, negative-sense, viral genomic RNA (vRNA) of influenza A virus is encapsidated by viral nucleoproteins (NPs) and an RNA polymerase to form a ribonucleoprotein complex (vRNP) with a helical, rod-shaped structure. The vRNP is responsible for transcription and replication of the vRNA. However, the vRNP conformation during RNA synthesis is not well understood. Here, using high-speed atomic force microscopy and cryo-electron microscopy, we investigated the native structure of influenza A vRNPs during RNA synthesis in vitro. Two distinct types of vRNPs were observed in association with newly synthesized RNAs: an intact, helical rod-shaped vRNP connected with a folded RNA and a deformed vRNP associated with a looped RNA. Interestingly, the looped RNA was a double-stranded RNA, which likely comprises a nascent RNA and the template RNA detached from NPs of the vRNP. These results suggest that while some vRNPs keep their helical structures during RNA synthesis, for the repeated cycle of RNA synthesis, others accidentally become structurally deformed, which likely results in failure to commence or continue RNA synthesis. Thus, our findings provide the ultrastructural feature of vRNPs during RNA synthesis.
    展開

    關(guān)鍵詞:RiboMAX體外轉(zhuǎn)錄,病毒研究,RNA合成

    應(yīng)用產(chǎn)品:RiboMAX? Large-Scale RNA Production SystemsRibo m7G Cap Analog

  • 使用許可的減毒活黃病毒疫苗作為骨架開發(fā)嵌合寨卡疫苗

    Nature Communications | 2018 | 查看原文 |

    作者:Xiao-Feng Li, Hao-Long Dong, Hong-Jiang Wang, Xing-Yao Huang, Ye-Feng Qiu, Xue Ji, Qing Ye, Chunfeng Li, Yang Liu, Yong-Qiang Deng, Tao Jiang, Gong Cheng, Fu-Chun Zhang, Andrew D. Davidson&#

    摘要:The global spread of Zika virus (ZIKV) and its unexpected association with congenital defects necessitates the rapid development of a safe and effective vaccine. Here we report the development and characterization of a recombinant chimeric ZIKV vaccine candidate (termed ChinZIKV) that expresses the prM-E proteins of ZIKV using the licensed Japanese encephalitis live-attenuated vaccine SA14-14-2 as the genetic backbone. ChinZIKV retains its replication activity and genetic stability in vitro, while exhibiting an attenuation phenotype in multiple animal models. Remarkably, immunization of mice and rhesus macaques with a single dose of ChinZIKV elicits robust and long-lasting immune responses, and confers complete protection against ZIKV challenge. Significantly, female mice immunized with ChinZIKV are protected against placental and fetal damage upon ZIKV challenge during pregnancy. Overall, our study provides an alternative vaccine platform in response to the ZIKV emergency, and the safety, immunogenicity, and protection profiles of ChinZIKV warrant further clinical development.
    展開

    關(guān)鍵詞:RiboMAX體外轉(zhuǎn)錄,病毒研究,疫苗研發(fā)

    應(yīng)用產(chǎn)品:RiboMAX? Large-Scale RNA Production SystemsRibo m7G Cap Analog

  • 地高辛和哇巴因針對SARS-CoV-2感染的抗病毒活性及其對COVID-19的影響

    Scientific Reports | 2020 | 查看原文 |

    作者:Junhyung Cho, Young Jae Lee, Je Hyoung Kim, Sang il Kim, Sung Soon Kim, Byeong-Sun Choi & Jang-Hoon Choi

    摘要:The current coronavirus (COVID-19) pandemic is exacerbated by the absence of effective therapeutic agents. Notably, patients with COVID-19 and comorbidities such as hypertension and cardiac diseases have a higher mortality rate. An efficient strategy in response to this issue is repurposing drugs with antiviral activity for therapeutic effect. Digoxin (DIG) and ouabain (OUA) are FDA drugs for heart diseases that have antiviral activity against several coronaviruses. Thus, we aimed to assess antiviral activity of DIG and OUA against SARS-CoV-2 infection. The half-maximal inhibitory concentrations (IC50) of DIG and OUA were determined at a nanomolar concentration. Progeny virus titers of single-dose treatment of DIG, OUA and remdesivir were approximately 103-, 104- and 103-fold lower (>?99% inhibition), respectively, than that of non-treated control or chloroquine at 48h post-infection (hpi). Furthermore, therapeutic treatment with DIG and OUA inhibited over 99% of SARS-CoV-2 replication, leading to viral inhibition at the post entry stage of the viral life cycle. Collectively, these results suggest that DIG and OUA may be an alternative treatment for COVID-19, with potential additional therapeutic effects for patients with cardiovascular disease.
    展開

    關(guān)鍵詞:RiboMAX體外轉(zhuǎn)錄,SARS-CoV-2,COVID-19

    應(yīng)用產(chǎn)品:RiboMAX? Large-Scale RNA Production SystemsRibo m7G Cap Analog

篩選項(xiàng)
清空
研究/應(yīng)用方向
產(chǎn)品/技術(shù)
取消
確認(rèn)